All In Biotech

Drug Trial Radar · NCT00587015

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Last checked: Nov 20, 2026Latest source record: Nov 22, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 2007

Primary completion

Mar 2008

Study completion Oct 2009

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.

Conditions

  • Lymphoma

Interventions

  • CAT-8015Drug

    The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess safety, estimate MTD, characterize toxicity profile, study pharmacology and observe anti-tumor activity at the MTD.Time frame: Day 28

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California

  • NCI, National Institutes of Health

    Bethesda, Maryland

  • Kalinika Hemotologii Uniwersytetu Medycznego

    Lodz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.